Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024
April 16, 2024 08:00 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business...
Absci to Participate in the 23rd Annual Needham Virtual Healthcare Conference
March 28, 2024 16:05 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be...
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results
March 21, 2024 07:30 ET
|
Absci Corporation
Initiated IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody Entered into collaboration with AstraZeneca for up to $247M in deal value, plus royalties Strengthened...
Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
March 01, 2024 16:01 ET
|
Absci Corporation
VANCOUVER, Wash., March 01, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today announced the closing of its underwritten...
Absci Announces Pricing of Public Offering of Common Stock
February 27, 2024 22:20 ET
|
Absci Corporation
VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today announced the pricing of an underwritten...
Absci Announces Proposed Public Offering of Common Stock
February 27, 2024 16:01 ET
|
Absci Corporation
VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, announced today that it has commenced an...
Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI
February 21, 2024 07:30 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the initiation of IND-enabling...
Absci to Participate in Upcoming Investor Conferences
February 20, 2024 08:00 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the...
Absci Appoints Professor Sir Mene Pangalos to its Board of Directors
January 10, 2024 07:30 ET
|
Absci Corporation
Sir Pangalos is a distinguished biopharmaceutical executive who led BioPharmaceuticals R&D at AstraZeneca. In addition to joining Absci’s Board, Sir Pangalos will co-chair Absci’s Scientific...
Absci to Present Preclinical Data for ABS-101, A Potential Best-in-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024 07:00 ET
|
Absci Corporation
Preclinical data support profile for development of a potential best-in-class drug IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after VANCOUVER, Wash....